Summary
Introduction
G protein coupled receptors (GPCRs) are nature's most versatile biological sensors and are responsible for the majority of cellular responses to hormones and neurotransmitters, as well as for the senses of sight, smell and taste. Our current models of the mechanism of GPCR activation by diffusible agonists have been deduced from indirect measures of receptor conformation, such as G protein or second messenger activation (1) (2) (3) (4) . These indirect assays of GPCR activity provide only limited insight into the agonist-induced structural changes that define the active state of the receptor.
To elucidate of the mechanism of GPCR activation by diffusible agonists, we developed a means for directly monitoring the active conformation of purified, detergent-solubilized β 2 adrenergic receptor (β 2 AR) by site-specific labeling of an endogenous cysteine (Cys265) with fluorescein maleimide (FM-β 2 AR) (5) . Based on homology with rhodopsin (6), Cys265 is located in the third intracellular loop (IC3) at the cytoplasmic end of the transmembrane 6 (TM6) α helix (Fig. 1A) .
Mutagenesis studies have shown this region of IC3 to be important for G protein coupling (7, 8) . An environmentally sensitive fluorophore covalently bound to Cys265 is therefore well positioned to detect agonistinduced conformational changes relevant to G protein activation. The effect of agonists and partial agonists on the fluorescence intensity of FMby on February 12, 2008 www.jbc.org Downloaded from β 2 AR correlates well with their biological properties (5) . Binding of the full agonist isoproterenol induces a conformational change that decreases the fluorescence intensity of FM bound to Cys265 by ~15% (Fig. 1B) , while binding of partial agonists results in smaller changes in intensity and binding of an antagonist has no effect (5).
Agonist-induced movement of FM bound to Cys265 was characterized by examining the interaction between the fluorescein at Cys265 and fluorescence quenching reagents localized to different molecular environments of the receptor. The results of these experiments are most consistent with either a clockwise rotation of TM6 and/or a tilting of the cytoplasmic end of TM6 toward TM5 (5). Our findings suggest that the conformational changes associated with β 2 AR activation are similar to those in rhodopsin (9) and indicate a shared mechanism of GPCR activation.
These results provide insight into the nature of the structural changes that occur upon agonist binding. However several mechanistic questions remain. Using conventional spectroscopy, we observe no change in the fluorescence intensity from FM−β 2 AR upon antagonist binding. 
Experimental Procedures
Fluorescence spectroscopic studies of the 2 AR-Construction, expression and purification of human β 2 AR were performed as described (10) .
Purified, detergent-solublized wild-type receptor was labeled with fluorescein maleimide (FM; Molecular Probes) as previously described 
where is the center value of the lifetime distribution and σ is the standard deviation of the Gaussian, which is related to the full width at half-maximum by 2.354 σ. In the frequency domain, the measured quantities at each frequency ω, are the phase shift (φ ω ) and demodulation factor (m ω ) of the emitted light versus the reference light.
Fractional intensity, amplitude, and lifetime parameters were recovered by a non-linear least squares procedure using the software developed at the Center for Fluorescence Spectroscopy. The measured data were compared with calculated values ( c ,m c ) and the goodness of fit was 
Results and Discussion
Using fluorescence lifetime spectroscopy to study ligand-induced conformational changes in the 2 AR.
The β 2 AR was purified and labeled at Cys265 with fluorescein maleimide to generate FM-β 2 AR as previously described (5). We (Fig. 2) .
The mobility of fluorescein relative to the receptor is minimal, as determined by its high measured anisotropy (r = 0.30 ± 0.02, n = 3), and therefore would be expected to contribute little to the width of the lifetime distribution. Thus, the width of the distribution can be attributed to conformational flexibility in the receptor itself.
Lifetime analysis of unliganded FM-β 2 AR reveals a single, flexible state. This is indicated by both the single, broad Gaussian distribution of lifetimes centered around 4.2 ns (Fig. 2, black trace) , and the discrete component analysis, where the fluorescence decay rate of FM-β 2 AR in the absence of any drug is best fit by a single exponential function ( Table 1) .
Binding of the neutral antagonist ALP to FM-β 2 AR does not significantly change the fluorescent lifetime (Table 1) , but does narrow the distribution of lifetimes (Fig. 2 , red trace), suggesting that ALP stabilizes the receptor and reduces conformational fluctuations. This interpretation is consistent with the results of experiments demonstrating that the β 2 AR is more resistant to protease digestion when bound to ALP (19).
Agonists and partial agonists induce distinct conformations
Unexpectedly, binding of the full agonist ISO promotes conformational heterogeneity. In the presence of saturating concentrations of ISO, FM-β 2 AR has two distinguishable fluorescence lifetimes (Fig 2, green trace, and Fig. 3 ). The long lifetime component found in the presence of these two partial agonists is indistinguishable from that observed in the ISO-bound receptor; however, the short lifetime component found in both the SAL-and DOB-bound receptor is statistically different from that for the ISO-bound receptor.
We observe a strong correlation between a reduction in fluorescence intensity of FM bound to Cys265 and drug efficacy (5) 
Models of GPCR activation
According to the prevailing two-state model of GPCR activation, receptors exist in an equilibrium between a resting (R) state and an active (R*) state which stimulates the G protein (20) (21) (22) . Agonists preferentially enrich the R* state, while inverse agonists select for the R state of the receptor. Neutral antagonists possess an equal affinity for both states and function simply as competitors. In this simple system, functional differences between drugs can be explained by their relative affinity for the single active R* state (Fig. 4A) . Alternatively, differences in efficacy between drugs can be due to ligand-specific receptor states (23) (24) (25) . 
Conclusions.
Our results have implications for drug discovery and efforts to obtain high resolution crystal structures of GPCRs. The conformational flexibility observed in the ligand-free receptor (Fig. 2 ) may make it particularly challenging to obtain crystals in the absence of a bound ligand. Of greater concern, the existence of two conformational states in the presence of saturating concentrations of full and partial agonists ( 
